Chardan Capital set a $18.00 target price on Arcturus Therapeutics (NASDAQ:ARCT) in a research note published on Thursday morning, Stock Target Advisor reports. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other brokerages have also commented on ARCT. Zacks Investment Research upgraded Arcturus Therapeutics from a sell rating to a hold rating in a research report on Monday, March 18th. ValuEngine lowered Arcturus Therapeutics from a hold rating to a sell rating in a research report on Monday, June 17th. HC Wainwright assumed coverage on Arcturus Therapeutics in a research report on Friday, April 5th. They set a buy rating and a $15.00 target price for the company. Finally, Roth Capital restated a buy rating on shares of Arcturus Therapeutics in a research report on Wednesday, February 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Arcturus Therapeutics has an average rating of Buy and a consensus target price of $13.83.
Shares of ARCT stock opened at $9.74 on Thursday. The company has a debt-to-equity ratio of 2.43, a current ratio of 2.51 and a quick ratio of 2.51. The stock has a market capitalization of $104.82 million, a P/E ratio of -4.51 and a beta of 2.10. Arcturus Therapeutics has a 12 month low of $4.11 and a 12 month high of $10.29.
Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Monday, May 13th. The biotechnology company reported ($0.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.15). The firm had revenue of $4.35 million during the quarter, compared to analyst estimates of $3.47 million. Arcturus Therapeutics had a negative return on equity of 132.46% and a negative net margin of 124.59%. Equities analysts anticipate that Arcturus Therapeutics will post -2.41 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the company. Nikko Asset Management Americas Inc. acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at approximately $438,000. ARK Investment Management LLC grew its position in shares of Arcturus Therapeutics by 13.7% in the 1st quarter. ARK Investment Management LLC now owns 927,144 shares of the biotechnology company’s stock valued at $6,332,000 after purchasing an additional 111,968 shares during the period. Finally, Creative Planning acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at approximately $416,000. Institutional investors own 13.58% of the company’s stock.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.
Further Reading: What is a back-end load?
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.